Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus KS400
- Development stage
- Unknown
- Lead developer
- Medinova
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Lactobacillus acidophilus KS400 is a probiotic bacterial strain that serves as the active ingredient in Gynoflor, a vaginal tablet developed by Medinova AG. It is a live biotherapeutic modality administered vaginally to restore the healthy vaginal microbiome, treat vaginal atrophy, and prevent the recurrence of bacterial vaginosis. L. acidophilus KS400 works by colonizing the vaginal epithelial surface and producing antimicrobial metabolites, including lactic acid, hydrogen peroxide, and a ~7.5 kDa bacteriocin. These metabolites inhibit the growth of urogenital pathogens such as Gardnerella vaginalis, Streptococcus agalactiae, and Pseudomonas aeruginosa. In clinical trials, it has been evaluated both as a monotherapy and in combination with ultra-low-dose estriol (oestriol) to promote vaginal epithelial maturation and re-establish a protective lactobacillary flora.
- Other names
- L. acidophilus KS400LaKS400LaKS-400LaKS 400
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on Lactobacillus acidophilus KS400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus KS400.